Tenderwize
Back to tender search

Pharmaceutical discount agreements for Lamivudine, Abacavir and Dolutegravir

AOK Rheinland-Pfalz/Saarland - Die Gesundheitskasse·Eisenberg, Germany·Deadline Jun 30, 2027 · 222 days left·Open·Supplies
Original notice title

Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge zum Wirkstoff Lamivudin, Abacavir und Dolutegravir, ATC J05AR13

55/100

Opportunity Score

Needs reviewHigh complexity
SuppliesOpen
Why this score?

Opportunity

55 / 100

Complexity

67 / 100

Risk factors

No estimated value, purchasing volume or guaranteed spend is stated in the provided data.

The buyer expressly reserves the right to replace the open-house agreements with exclusive rebate contracts, after whic...

Deep Portfolio Analysis

Deep Company Fit Analysis

Uses:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Tender facts

Contracting authority
AOK Rheinland-Pfalz/Saarland - Die Gesundheitskasse
Country
Germany
CPV
33600000 - Pharmaceutical products
Deadline
Jun 30, 2027

Overview

Moderate opportunity

Key Facts

  • Supplies contract
  • 1 lot
  • Duration until Aug 2027
  • Conclusion of non-exclusive pharmaceutical rebate agreements under sections 130a(8) and 130c(1) SGB V.
  • Active ingredients covered: Lamivudine, Abacavir and Dolutegravir, ATC J05AR13.
Show full summary

Open-house, non-exclusive pharmaceutical rebate agreements for Lamivudine, Abacavir and Dolutegravir (ATC J05AR13) with AOK Rheinland-Pfalz/Saarland. All interested pharmaceutical companies may join under identical, non-negotiable conditions without a selection decision. Contracts may be concluded monthly from 1 September 2025 through the 24-month operating period, subject to the applicable receipt deadlines. Procurement documents are available through DTVP but their extracted contents were not provided; therefore commercial terms, detailed obligations and full submission requirements remain unverified.

Risks

No estimated value, purchasing volume or guaranteed spend is stated in the provided data.

The buyer expressly reserves the right to replace the open-house agreements with exclusive rebate contracts, after whic...

Analysis may be incomplete

Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.

Key Requirements

Technical

  • Only pharmaceutical companies may participate.

Administrative

  • The open-house contracts are non-exclusive and use uniform conditions; individual negotiations are not conducted.
  • Contract documents may be submitted either as two signed paper copies or electronically with a qualified electronic signature.

Buyer

Lots (1)

LOT-0001

Open-house pharmaceutical rebate agreements for Lamivudine, Abacavir and Dolutegravir

Non-exclusive rebate agreements under the open-house model for medicines containing Lamivudine, Abacavir and Dolutegravir, ATC J05AR13. All participating pharmaceutical companies receive uniform conditions and no individual negotiations are conducted. Medicines on the BfArM list under section 35(5a) SGB V for paediatric medicines are excluded. Contract information and conditions are available only after registration and release through DTVP.

SuppliesEU fundedElectronic submission

Location

Eisenberg, Germany

Duration

Aug 2025 - Aug 2027

Category

Pharmaceutical products

Deadline

Deadline Jun 30, 2027

Procurement Details

Publication date
13 Jul 2025
Languages
German

Reference metadata

Legal basis
32014L0024

Reference IDs

Tender ID
457211-2025

Documents (1)

Similar tenders

Cookies & Privacy

With your consent, we use Google Analytics, Microsoft Clarity (session recordings) and Google Ads cookies to understand how Tenderwize is used and to measure our advertising. You can change your choice at any time via “Cookie Settings” in the footer. Cookie Policy · Privacy Policy